Skip to main content
Ibiayi Dagogo-Jack, MD, Oncology, Boston, MA

IbiayiDagogo-JackMD

Oncology • Boston, MA

Thoracic Cancer

Thoracic Oncologist

Join to view full profile

Dr. Dagogo-Jack is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Dagogo-Jack's full profile

Already have an account?

  • Office

    55 Fruit St Yawkey 7B
    Boston, MA 02114
    Phone+1 617-724-4000

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2014 - 2017
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2011 - 2014
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2011

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2015 - 2026
  • NH State Medical License
    NH State Medical License 2021 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Inductee Alpha Omega Alpha Honor Medical Society, 2011

Publications & Presentations

PubMed

Lectures

  • Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer (NSCLC). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • Lung Cancer Research Foundation Creates Scientific Executive Committee
    Lung Cancer Research Foundation Creates Scientific Executive CommitteeJuly 11th, 2022
  • Join VA and the White House Today for a Cancer Cabinet Community Conversation
    Join VA and the White House Today for a Cancer Cabinet Community ConversationMay 4th, 2022
  • In Expected Decision, FDA Rejects Lilly's Sintilimab in NSCLC
    In Expected Decision, FDA Rejects Lilly's Sintilimab in NSCLCMarch 24th, 2022
  • Join now to see all

Professional Memberships

Dr. Ibiayi Dagogo-Jack, Dr. Ibiayi Dagogo-Jack, MD, Dr. I Dagogo-Jack